NovaCura BioAI
Transforming the Undruggable with AI & Biology
Next-generation therapies for fibrosis & oncology through STAT3-targeted innovation.
Our Highlights
Pipeline Innovation
Lead candidate TTI-101 targets the "undruggable" STAT3 pathway with promising clinical results in both IPF and HCC trials.
Technology Platform
Our AI-driven discovery platform combines molecular modeling and integrated data analysis to accelerate drug development.
Experienced Leadership
Our team combines expertise in neuropharmacology, medicinal chemistry, and AI-driven drug discovery from leading institutions.
Our Vision
"To merge AI with biotechnology to break traditional drug development boundaries, delivering more precise, effective, and accessible therapies. We aim to transform targets once considered 'undruggable' into real clinical solutions, rewriting the future of human health."
Dr. Tag Horner, PhD., D.Sc.
President & CEO
Latest News & Research
STAT3 Inhibition Shows Promise in IPF Mouse Models
Our latest research publication demonstrates significant improvements in fibrotic lung tissue when treated with our lead STAT3 inhibitor candidate...
Read PublicationPreliminary Results of TTI-101 in Patients with Idiopathic Pulmonary Fibrosis
This publication presents promising interim results from the RENEW-IPF Phase 2 trial, showing TTI-101's favorable safety profile and efficacy signals in IPF patients...
Read PublicationNovaCura BioAI Announces Strategic AI Partnership
NovaCura BioAI announces NuxtLink new strategic partnership to leverage advanced machine learning algorithms for drug discovery acceleration...
Read Press ReleaseDiscover How We're Redefining Drug Development
Join us on our mission to transform undruggable targets into viable therapeutic opportunities. Learn more about our innovative approach, pipeline progress, and investment opportunities.